3/5
04:22 pm
eols
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]
Medium
Report
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]
3/4
04:56 pm
eols
Evolus, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Evolus, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/4
08:00 am
eols
Evolus (EOLS) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.
High
Report
Evolus (EOLS) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.
3/4
02:48 am
eols
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/4
02:47 am
eols
Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio [Seeking Alpha]
High
Report
Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio [Seeking Alpha]
3/4
12:15 am
eols
Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges [Yahoo! Finance]
High
Report
Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges [Yahoo! Finance]
3/3
07:17 pm
eols
Evolus Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
Evolus Q4 Earnings Call Highlights [Yahoo! Finance]
3/3
06:25 pm
eols
Evolus (EOLS) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
High
Report
Evolus (EOLS) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/3
04:20 pm
eols
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026 [Yahoo! Finance]
High
Report
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026 [Yahoo! Finance]
3/3
04:05 pm
eols
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026
High
Report
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026
2/25
08:00 am
eols
Evolus to Participate in The Leerink Partners Global Healthcare Conference
Medium
Report
Evolus to Participate in The Leerink Partners Global Healthcare Conference
2/17
08:40 am
eols
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026 [Yahoo! Finance]
Low
Report
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026 [Yahoo! Finance]
2/17
08:00 am
eols
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
Low
Report
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
2/13
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/9
02:43 pm
eols
Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating [Yahoo! Finance]
Low
Report
Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating [Yahoo! Finance]
2/4
10:15 am
eols
Evolus (NASDAQ:EOLS) was given a new $15.00 price target on by analysts at Mizuho.
Low
Report
Evolus (NASDAQ:EOLS) was given a new $15.00 price target on by analysts at Mizuho.
2/4
08:01 am
eols
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance]
Low
Report
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance]
2/4
07:56 am
eols
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance Canada]
Low
Report
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance Canada]
2/3
08:03 am
eols
Evolus (NASDAQ:EOLS) had its price target lowered by analysts at HC Wainwright from $20.00 to $13.00. They now have a "buy" rating on the stock.
Medium
Report
Evolus (NASDAQ:EOLS) had its price target lowered by analysts at HC Wainwright from $20.00 to $13.00. They now have a "buy" rating on the stock.
1/26
08:17 am
eols
How A New Price Target Is Shaping The Evolus (EOLS) Story [Yahoo! Finance]
Low
Report
How A New Price Target Is Shaping The Evolus (EOLS) Story [Yahoo! Finance]
1/22
08:06 am
eols
Evolus (NASDAQ:EOLS) had its price target lowered by analysts at BTIG Research from $18.00 to $13.00. They now have a "buy" rating on the stock.
Low
Report
Evolus (NASDAQ:EOLS) had its price target lowered by analysts at BTIG Research from $18.00 to $13.00. They now have a "buy" rating on the stock.
1/13
09:02 am
eols
Evolus (NASDAQ:EOLS) was given a new $17.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Evolus (NASDAQ:EOLS) was given a new $17.00 price target on by analysts at Stifel Nicolaus.
1/9
07:03 pm
eols
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue [Yahoo! Finance]
Low
Report
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue [Yahoo! Finance]
1/9
12:46 pm
eols
Evolus (NASDAQ:EOLS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Evolus (NASDAQ:EOLS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
1/9
09:01 am
eols
Evolus sees Q4 net revenue between $88.6M and $90.6M [Seeking Alpha]
Low
Report
Evolus sees Q4 net revenue between $88.6M and $90.6M [Seeking Alpha]